NICE - Endorsed Technology Appraisals 2018/2019

It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

Technology Appraisals Endorsement Process

The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland.  The new arrangements are detailed in following circulars, which is effective from 18th December 2013;

NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.

For information, details of the previous arrangement can be found on the following circular;

NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11

2018/2019

The following technology appraisals have been endorsed during 2017/18. Information on technology appraisals endorsed in previous years can be found on the homepage. 

Fully Endorsed 

March 2019

NICE TA 540 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma

NICE TA 553 - Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence

NICE TA 557 - Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer

NICE TA 554 - Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged ups to 25 years

NICE TA 558 - Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease

NICE TA 561 - Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia

NICE TA 562 - Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma

NICE TA 563 - Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

February 2019

NICE TA 487 - Venetoclax for treating chronic lymphocytic leukaemia

NICE TA 490 - Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy 

NICE TA 491 - Ibrutinib for treating Waldenstrom’s macroglobulinaemia

NICE TA 492 - Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

NICE TA 505 - Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma

NICE TA 510 - Daratumumab monotherapy for treating relapsed and refractory multiple myeloma

NICE TA 517 - Avelumab for treating metastatic Merkel cell carcinoma

  • This update and replaces NICE TA 517 - Avelumab for treating meteatatic Merkel cell carcinoma, which was endorsed by the DoH in May 2018.

NICE TA 519 - Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

NICE TA 522 - Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable

NICE TA 529 - Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer

January 2019

NICE TA 550 - Vandetanib for treating medullary thyroid cancer

NICE TA 551 - Lenvatinib for untreated advanced hepatocellular carcinoma

NICE TA 552 - Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia

NICE TA 555 - Regorafenib for previously treated advanced hepatocellular carcinoma (rapid review of TA514)

  • This guidance updates and replaces NICE Technology Appraisal TA514, which was endorsed by the DoH in April 2018.

NICE TA 556Darvadstrocel for treating complex perianal fistulas in Crohn’s disease

NICE TA 472 - Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab Note this guidance has been updated and replaced by TA629 - Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab, which was endorsed by the DoH in July 2020

NICE TA 483 - Nivolumab for previously treated squamous non-small-cell lung cancer

NICE TA 528 - Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer

NICE TA 484 - Nivolumab for previously treated non-squamous non-small-cell lung cancer

December 2018

NICE TA 547 - Tofacitinib for moderately to severely active ulcerative colitis

November 2018

NICE TA 544 - Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma

NICE TA 545 - Gemtuzumab ozogamicin for untreated acute myeloid leukaemia

NICE TA 546 - Padeliporfin for untreated localised prostate cancer

October 2018

NICE TA 541 - Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia

NICE TA 542 - Cabozantinib for untreated advanced renal cell carcinoma

NICE TA 543 - Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs

September 2018

NICE TA 538 - Dinutuximab beta for treating neuroblastoma

NICE TA 537 - Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs

NICE TA 536 - Alectinib for untreated ALK-positive advanced non-small-cell lung cancer

NICE TA 535 - Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine

NICE TA 539 - Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours

August 2018

NICE TA 532 - Cenegermin for treating neurotrophic keratitis

NICE TA 527 - Beta interferons and glatiramer acetate for treating multiple sclerosis (review of TA32)

NICE TA 530 - Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy

NICE TA 531 - Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (review of TA447)

NICE TA 533 - Ocrelizumab for treating relapsing–remitting multiple sclerosis 

NICE TA 534 - Dupilumab for treating moderate to severe atopic dermatitis

June 2018

NICE TA 520 - Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy

NICE TA 521 - Guselkumab for treating moderate to severe plaque psoriasis

NICE TA 523 - Midostaurin for untreated acute myeloid leukaemia

NICE TA 524 - Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (review of TA446)

  • This guidance updates and replaces NICE Technology Appraisal TA446, which was endorsed by the DoH in July 2017.

NICE TA 525 - Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy

May 2018

NICE TA 518 - Tocilizumab for treating giant cell arteritis

April 2018

NICE TA 511 - Brodalumab for treating moderate to severe plaque psoriasis

NICE TA 512 - Tivozanib for treating advanced renal cell carcinoma

NICE TA 513 - Obinutuzumab for untreated advanced follicular lymphoma

NICE TA 514 - Regorafenib for previously treated advanced hepatocellular carcinoma

NICE TA 515 - Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (review of TA250)

  • This guidance updates and replaces NICE Technology Appraisal TA250, which was endorsed by the DoH in May 2012.

NICE TA 516 - Cabozantinib for treating medullary thyroid cancer

Back to top